Literature DB >> 24269589

Peptides derived from human galectin-3 N-terminal tail interact with its carbohydrate recognition domain in a phosphorylation-dependent manner.

M Álvaro Berbís1, Sabine André2, F Javier Cañada1, Rüdiger Pipkorn3, Hans Ippel4, Kevin H Mayo5, Dieter Kübler6, Hans-Joachim Gabius2, Jesús Jiménez-Barbero7.   

Abstract

Galectin-3 (Gal-3) is a multi-functional effector protein that functions in the cytoplasm and the nucleus, as well as extracellularly following non-classical secretion. Structurally, Gal-3 is unique among galectins with its carbohydrate recognition domain (CRD) attached to a rather long N-terminal tail composed mostly of collagen-like repeats (nine in the human protein) and terminating in a short non-collagenous terminal peptide sequence unique in this lectin family and not yet fully explored. Although several Ser and Tyr sites within the N-terminal tail can be phosphorylated, the physiological significance of this post-translational modification remains unclear. Here, we used a series of synthetic (phospho)peptides derived from the tail to assess phosphorylation-mediated interactions with (15)N-labeled Gal-3 CRD. HSQC-derived chemical shift perturbations revealed selective interactions at the backface of the CRD that were attenuated by phosphorylation of Tyr 107 and Tyr 118, while phosphorylation of Ser 6 and Ser 12 was essential. Controls with sequence scrambling underscored inherent specificity. Our studies shed light on how phosphorylation of the N-terminal tail may impact on Gal-3 function and prompt further studies using phosphorylated full-length protein.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Agglutinin; CRD; Collagen; Gal-3; HSQC; Lectin; NMR; Phosphopeptide; Phosphorylation; carbohydrate recognition domain; galectin-3; heteronuclear single-quantum coherence; nuclear magnetic resonance

Mesh:

Substances:

Year:  2013        PMID: 24269589     DOI: 10.1016/j.bbrc.2013.11.063

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Preliminary X-ray crystallographic analysis of an engineered variant of human chimera-type galectin-3 with a shortened N-terminal domain.

Authors:  Andrea Flores-Ibarra; Federico M Ruiz; Sabine Vértesy; Sabine André; Hans-Joachim Gabius; Antonio Romero
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-01-28       Impact factor: 1.056

2.  Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR.

Authors:  Hans Ippel; Michelle C Miller; Sabine Vértesy; Yi Zheng; F Javier Cañada; Dennis Suylen; Kimiko Umemoto; Cecilia Romanò; Tilman Hackeng; Guihua Tai; Hakon Leffler; Jürgen Kopitz; Sabine André; Dieter Kübler; Jesús Jiménez-Barbero; Stefan Oscarson; Hans-Joachim Gabius; Kevin H Mayo
Journal:  Glycobiology       Date:  2016-02-23       Impact factor: 4.313

3.  A chimeric, multivalent assembly of galectin-1 and galectin-3 with enhanced extracellular activity.

Authors:  Margaret M Fettis; Shaheen A Farhadi; Gregory A Hudalla
Journal:  Biomater Sci       Date:  2019-04-23       Impact factor: 6.843

4.  The intrinsically disordered N-terminal domain of galectin-3 dynamically mediates multisite self-association of the protein through fuzzy interactions.

Authors:  Yu-Hao Lin; De-Chen Qiu; Wen-Han Chang; Yi-Qi Yeh; U-Ser Jeng; Fu-Tong Liu; Jie-Rong Huang
Journal:  J Biol Chem       Date:  2017-09-11       Impact factor: 5.157

5.  Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.

Authors:  Michelle C Miller; Hans Ippel; Dennis Suylen; Anatole A Klyosov; Peter G Traber; Tilman Hackeng; Kevin H Mayo
Journal:  Glycobiology       Date:  2016-01       Impact factor: 4.313

Review 6.  Galectin-3 as a regulator of the epithelial junction: Implications to wound repair and cancer.

Authors:  Pablo Argüeso; Jerome Mauris; Yuichi Uchino
Journal:  Tissue Barriers       Date:  2015-03-17

7.  Glycan dependence of Galectin-3 self-association properties.

Authors:  Hubert Halimi; Annafrancesca Rigato; Deborah Byrne; Géraldine Ferracci; Corinne Sebban-Kreuzer; Latifa ElAntak; Francoise Guerlesquin
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

Review 8.  Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments.

Authors:  Ana Carolina Ferreira Cardoso; Luciana Nogueira de Sousa Andrade; Silvina Odete Bustos; Roger Chammas
Journal:  Front Oncol       Date:  2016-05-23       Impact factor: 6.244

9.  Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis.

Authors:  Carrie A Duckworth; Scott E Guimond; Paulina Sindrewicz; Ashley J Hughes; Neil S French; Lu-Yun Lian; Edwin A Yates; D Mark Pritchard; Jonathan M Rhodes; Jeremy E Turnbull; Lu-Gang Yu
Journal:  Oncotarget       Date:  2015-09-15

Review 10.  Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.

Authors:  Navin Suthahar; Wouter C Meijers; Herman H W Silljé; Jennifer E Ho; Fu-Tong Liu; Rudolf A de Boer
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.